Skip to main content
. 2020 Apr 7;9(1):1746554. doi: 10.1080/2162402X.2020.1746554

Figure 2.

Figure 2.

Survival analysis according to CD200 or CD200R1 expression in patients with non-small cell lung cancer (NSCLC).

(a–c) Kaplan–Meier curves for overall survival (OS), recurrence-free survival (RFS), and cancer-specific survival (CSS) based on tumoral CD200 (a), tumoral CD200R1 (b), or stromal CD200R1 expression. Patients were stratified based on a cutoff determined by the minimum P-value method for OS based on tumoral CD200 and CD200R1. Stromal CD200R1 was divided based on the median expression, such as grade 0–1 and grade 2–3.